The Global Microbiology Culture Market is estimated to be valued at USD 11.91 Bn in 2025 and is expected to reach USD 22.05 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 9.2% from 2025 to 2032. This significant growth reflects increasing demand for advanced microbiological techniques in healthcare, pharmaceuticals, and food industries, driven by rising infectious diseases and the need for quality control in manufacturing processes globally.
Current market trends highlight a growing emphasis on automation and high-throughput screening technologies in microbiology culture systems, enhancing precision and efficiency. Additionally, the expanding application of microbiology cultures in personalized medicine, biotechnology research, and environmental monitoring is further propelling the market growth. Strategic partnerships and continuous innovation in culture media formulations are also shaping the competitive landscape, enabling companies to capture a larger share of this rapidly evolving the market.
|
Current Events |
Description and its Impact |
|
Accelerated Adoption of Automation and AI |
|
|
The Rise of Antimicrobial Resistance (AMR) |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
The use of culture media is an integral part of the entire microbiological process of growing and isolating microorganisms or consequently, their signals from the environment, which is the reason for the microbiology culture segment leading position with a share valued at 44.5% in 2025. Hence, among different product types, culture media are the ones who take the upper hand through their widespread applications in clinical diagnostics, pharmaceutical research, food and beverage testing, and environmental monitoring.
In May 2025, PL BioScience, a German life sciences company, and DewCell Biotherapeutics, a Korean biotech firm, announced a partnership to develop scalable, animal-free cell culture media. DewCell will supply batches of artificial platelets, utilizing their stem cell differentiation technology to create megakaryocytes for production.
It is expected that bacterial culture would have 25.5% of the market share in 2025, a major factor being its indispensable application in the health, agriculture, and industry sectors. The market segment is being enriched by the concern related to the rise of bacterial infections and the problem of antimicrobial resistance.
The bacterial culture has become the center of attention in the research pertaining to pathogens, antibiotic resistance, and microbial ecology. The areas of application of this method are clinical diagnostics, environmental monitoring, food safety, and probiotic development. So, the ever-increasing demand for bacterial research and diagnostic testing keeps on providing with the necessary expansion of this segment.
It is predicted that liquid culture segment will reach a market share of 35.4% in 2025, which is based on the fact that the systems can support rapid, uniform microbial growth. The systems also keep the process of scaling up microbial cultivation going by maintaining even oxygenation and nutrient distribution, which are the significant factors in this kind of process.
Liquid cultures are mainly applied in clinical labs, biopharmaceutical production, and research and are thus classified as automated systems and high-throughput screening that are also very much dependent on liquid cultures. Their compatibility with bioreactors and diagnostic devices facilitates the microbial growth monitoring process, which is essential for the large-scale fermentation and biologics production in the pharmaceutical industry.

To learn more about this report, Download Free Sample
The microbiology culture market in North America is predicted to hold the biggest part by 40.5% share in 2025, mainly due to the strong and advanced healthcare infrastructure and the high research and investment in the biopharmaceutical industry. The region is also being supported by the presence of top microbiology culture manufacturers, such as Thermo Fisher Scientific, Becton Dickinson, and Merck KGaA, as they offer a wide range of products and actively participate in the development of new culture media and diagnostic technologies through their innovations.
In August 2024, Nucleus Biologics, a provider of high-quality cell culture media and related services, introduced its QuickStart Media platform in the U.S. The platform offers customizable, high-performance cell culture media for T cells, HEK cells, MSCs, and NK cells, accelerating therapy development and optimization.
The Asia Pacific region is predicted to take up 24.3% of the microbiology culture share in 2025, as a result of the fastest-growing healthcare sector across the world, increased incidence of infectious diseases, and growing consumers’ interest in diagnostics. Countries like China, India, and Japan have been investing heavily in the healthcare infrastructure and biopharmaceuticals, which eventually translates to demand for microbiology culture products.
Furthermore, the region is recognized for its growing demand for microbiology cultures in the food safety and pharmaceutical sectors, which are among the most industrialized industries and extensively use microbiology cultures for the quality control process. Prominent companies, such as bioMérieux (with a strong presence in China and India) and Eiken Chemical Co., are actively expanding their regional footprints by introducing localized and affordable solutions.
The U.S. microbiology culture market is infectious diseases and biotechnological research that the government strongly supports through NIH grants. Thermo Fisher Scientific and Becton Dickinson, the market leaders, push the innovation further with their high-tech culture media and automation technologies for clinical microbiology. The U.S. continues to have a strong demand for microbiology culture products due to high healthcare expenditure and the presence of numerous pharmaceutical and biotechnology companies.
In May 2021, BD (Becton, Dickinson and Company) launched the Urine Culture Application for the BD Kiestra lab automation system in the U.S., aiming to revolutionize microbiology labs' approach to urine culture analysis. This application leverages artificial intelligence (AI), digital imaging, and machine learning to analyze urine culture plates, reducing the manual workload.
The Germany microbiology culture market is a clear demonstration of the robustness of the pharmaceutical and life sciences sectors, with the likes of Merck KGaA being a key contributor of quality culture media and reagent products. The rigorous regulations that exist in the country guarantee the maintainability of product quality at high levels, and they are also a source of innovation and trustworthiness. Moreover, support from the government for research and biotechnological industries through programs like the Bioeconomy Strategy is a factor that drives the market's growth.
In May 2025, Molecular Devices launched the QPix FLEX Microbial Colony Picking System, designed to automate microbial screening with over 95% efficiency and nearly 100% accuracy. Ideal for research in microbial strain engineering and microbiome studies, including in Germany, it streamlines workflows, reduces manual labor, and ensures precise sample tracking.
China is actively transforming its microbiology culture market by increasing healthcare expenditure and implementing government innovative initiatives, such as the Healthy China 2030 plan. The market is active due to the presence of local and international competitors like bioMérieux and Danaher who are constantly involved in partnerships and joint ventures. One of the reasons for the biosafety media's growing demand for diagnostics and environmental monitoring is the vast pharmaceutical sector and the higher public health awareness.
In June 2025, WuXi Biologics broke ground on a new microbial production plant in Chengdu, China, marking a significant expansion. The 95,000-square-meter facility, set to be GMP-ready by the end of 2026, will feature China’s first dual-chamber lyophilization production line and a vial filling line. It will support various modalities, including peptides, antibody fragments, enzymes, and virus-like particles, with a total capacity exceeding 10 million vials annually.
The India microbiology culture market is characterized by rapid dynamic growth mainly due to the increased incidence of infectious diseases and the enhancement of clinical diagnostics infrastructure. Among other things, the government's support under the Ayushman Bharat program is making advanced healthcare services available to more people and thus, increasing the demand for microbiology culture products. One of the main local manufacturers, HiMedia Laboratories, is on the front line of the market by supplying cheap yet quality and innovative culture media.
In January 2025, India-based biotechnology startup CrisprBits inaugurated its CRISPR gene editing and diagnostics laboratory, aimed at advancing molecular diagnostics, rare disease research, and industrial microbiology applications. The facility is equipped with specialized sections for lyophilization, cell and tissue culture, bacterial culture, molecular biology research, and cleanroom operations.

To learn more about this report, Download Free Sample
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 11.91 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 9.2% | 2032 Value Projection: | USD 22.05 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Thermo Fisher Scientific, Merck KGaA, Sartorius AG, Danaher Corporation, Lonza Group Ltd, Becton, Dickinson and Company, Bio-Rad Laboratories, FUJIFILM Irvine Scientific, HiMedia Laboratories, Corning Incorporated, Avantor Inc, GE Healthcare, Ajinomoto Co Inc, Caisson Laboratories, and PAN-Biotech GmbH |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report

To learn more about this report, Download Free Sample
The increasing occurrence of infectious diseases all over the world is one of the main reasons behind the growth of the global microbiology culture market. With the infection-causing germs evolving and appearing more, the management of public health requires very accurate and quick detection. The use of microbiological cultures is the most basic way in identifying bacteria, fungi, and viruses; thus, giving the healthcare providers capacity to diagnose diseases, and then, suggest the correct treatment options. The increase in the number of infectious diseases that are resistant to antibiotics has, therefore, led to the situation where the investments of healthcare facilities and diagnostic laboratories in advanced microbiological culture technologies are considerable.
For instance, in April 2025, WHO, UNICEF, and Gavi warned that vaccine-preventable diseases are on the rise, jeopardizing decades of progress in global health. Outbreaks of diseases like measles, meningitis, TB and yellow fever have surged, with measles cases reaching an estimated 10.3 million in 2023, a 20% increase from 2022. Example is In October 2024, the World Health Organization (WHO) reported a rise in tuberculosis (TB) cases, with 8.2 million new diagnoses in 2023, the highest since monitoring began in 1995. This increase from 7.5 million in 2022 makes TB the leading infectious disease killer, surpassing COVID-19. Although TB-related deaths decreased from 1.32 million in 2022 to 1.25 million in 2023, the total number of TB cases rose to 10.8 million.
The global microbiology culture market is poised to reap a great deal of benefit from the recent developments and wider use of quick and automated culture systems. The classic microbiology culture methods, although very dependable, are usually taking much time to process, overworking the lab staff and thus sometimes becoming inaccurate due to the human error factor, which all in all causes the delay in diagnosis and treatment decisions. The patient of putting up with all these issues takes a turn with the help of the integration of automation and rapid culture technologies which actually cuts down the time taken by these processes and at the same time improves the accuracy of results significantly.
For example, Mindray introduced advanced microbiology assays for flow cytometry, providing key tools for assessing bacterial and yeast growth, vitality, and metabolic processes. Their LIVE/DEAD BacLight Bacterial Viability and Counting Kit enable efficient separation of live and dead bacteria based on membrane integrity, offering a fast and reliable method for bacterial viability analysis.
Share
Share
About Author
Nikhilesh Ravindra Patel is a Senior Consultant with over 8 years of consulting experience. He excels in market estimations, market insights, and identifying trends and opportunities. His deep understanding of the market dynamics and ability to pinpoint growth areas make him an invaluable asset in guiding clients toward informed business decisions. He plays a instrumental role in providing market intelligence, business intelligence, and competitive intelligence services through the reports.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients